Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer

References

• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–12. doi: 10.1016/S0140-6736(16)31891-8.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi: 10.1016/S1470-2045(17)30904-X.
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. 2006. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 295(21):2492. doi: 10.1001/jama.295.21.2492.
   PubMed Web of Science ®Google Scholar
• Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619–626. doi: 10.1158/1055-9965.EPI-17-0627.
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–113. doi: 10.1200/JCO.2009.23.7370.
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JPA, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–867. doi: 10.1200/JCO.2011.41.0902.
   PubMed Web of Science ®Google Scholar
• Würfel F, Erber R, Huebner H, Hein A, Lux MP, Jud S, Kremer A, Kranich H, Mackensen A, Häberle L, et al. 2018. Tilgen: a program to investigate immune targets in breast cancer patients - first results on the influence of tumor-infiltrating lymphocytes. Breast Care. 13(1):8–14. doi: 10.1159/000486949.
   PubMed Web of Science ®Google Scholar
• Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354–1360. doi: 10.1001/jamaoncol.2016.1061.
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C, Salgado R. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32(10):1236–1244. doi: 10.1016/j.annonc.2021.07.007.
   PubMed Web of Science ®Google Scholar
• Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandamh R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A. 2012;109(8):2802–2807. doi: 10.1073/pnas.1108781108.
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373–5380. doi: 10.1200/JCO.2006.05.9584.
   PubMed Web of Science ®Google Scholar
• Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology. 2011;58(7):1107–1116. doi: 10.1111/j.1365-2559.2011.03846.x.
   PubMed Web of Science ®Google Scholar
• Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8 +lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14(2). doi: 10.1186/bcr3148.
   Web of Science ®Google Scholar
• Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645–655. doi: 10.1007/s10549-011-1647-3.
   PubMed Web of Science ®Google Scholar
• Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K, Beck AH. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9(12):1–21. doi: 10.1371/journal.pone.0115103.
   Web of Science ®Google Scholar
• Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis e Sousa C. NK cells Stimulate Recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022–1028.e14. doi: 10.1016/j.cell.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, et al. 2018. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments. Nat Med. 24(8):1178–1191. doi: 10.1038/s41591-018-0085-8.
   PubMed Web of Science ®Google Scholar
• Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016;29(3):249–258. doi: 10.1038/modpathol.2015.158.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. 2014. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2(4):361–370. doi: 10.1158/2326-6066.CIR-13-0127.
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–2966. doi: 10.1200/JCO.2013.55.0491.
   PubMed Web of Science ®Google Scholar
• McInnes L, Healy J, Melville J, Großberger L. UMAP: uniform manifold approximation and projection for dimension reduction. J Open Source Softw. 2018 Feb 9;3(29):861. doi: 10.21105/joss.00861.
   Google Scholar
• Samusik N, Good Z, Spitzer MH, Davis KL, Nolan GP. Automated mapping of phenotype space with single-cell data. Nat Methods. 2016;13(6):493–496. doi: 10.1038/nmeth.3863.
   PubMed Web of Science ®Google Scholar
• Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24:S26–S35. doi: 10.1016/j.breast.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12(7):381–394. doi: 10.1038/nrclinonc.2015.73.
   PubMed Web of Science ®Google Scholar
• Krijgsman D, Hokland M, Kuppen PJK. The role of natural killer T cells in cancer-A phenotypical and functional approach. Front Immunol. 2018;9(FEB). doi: 10.3389/fimmu.2018.00367.
   PubMedGoogle Scholar
• Bakdash G, Buschow SI, Gorris MAJ, Halilovic A, Hato SV, Sköld AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-De Boer T, et al. 2016. Expansion of a BDCA1+ CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines. Cancer Res. 76(15):4332–4346. doi: 10.1158/0008-5472.CAN-15-1695.
   PubMed Web of Science ®Google Scholar
• Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, Griesbeck M, Butler A, Zheng S, Lazo S, et al. 2017. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science (80-). 356(6335):eaah4573. doi: 10.1126/science.aah4573.
   PubMed Web of Science ®Google Scholar
• Dutertre CA, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, Ng PY, van den Hoogen LL, Leong JY, Lee B, et al. 2019. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity. 51(3):573–589.e8. doi: 10.1016/j.immuni.2019.08.008.
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Duurland CL, Jordanova EJ, van Ham VJ, Ehsan I, Loof NM, Narang V, Dutertre CA, Ginhoux F, van Egmond SL, et al. CD163+ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. J Immunother Cancer. 2020;8(2):1–15. doi: 10.1136/jitc-2020-001053.
   Web of Science ®Google Scholar
• Bourdely P, Anselmi G, Vaivode K, Ramos RN, Missolo-Koussou Y, Hidalgo S, Tosselo J, Nuñez N, Richer W, Vincent-Salomon A, et al. Transcriptional and functional analysis of CD1c+ human dendritic cells Identifies a CD163+ subset priming CD8+CD103+ T cells. Immunity. 2020;1–18. doi: 10.1016/j.immuni.2020.06.002.
   Web of Science ®Google Scholar
• Heger L, Hofer TP, Bigley V, de Vries IJM, Dalod M, Dudziak D, Ziegler-Heitbrock L. Subsets of CD1c+ DCs: dendritic cell versus monocyte lineage. Front Immunol. 2020;11(September):1–11. doi: 10.3389/fimmu.2020.559166.
   PubMedGoogle Scholar
• Lichert F. Histologische Typen bei triple-negativem Brustkrebs charakterisiert. Geburtshilfe Frauenheilkd. 2023;83(3):234–235. doi: 10.1055/a-1985-2161.
   Google Scholar
• Würstlein R, Harbeck N. Immuntherapie bei Brustkrebs. Geburtshilfe Frauenheilkd. 2021;81(3):255–259. doi: 10.1055/a-1071-6595.
   Google Scholar
• Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nat Immunol. 2020;21(8):835–847. doi: 10.1038/s41590-020-0728-z.
   PubMed Web of Science ®Google Scholar
• Jacobs B, Gebel V, Heger L, Grèze V, Schild H, Dudziak D, Ullrich E. Characterization and manipulation of the crosstalk between dendritic and natural killer cells within the tumor microenvironment. Front Immunol. 2021;12(May):1–11. doi: 10.3389/fimmu.2021.670540.
   Google Scholar
• Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menendez S, Vazquez I, et al. NK cell infiltrates and HLA class I expression in primary HER2 þ breast cancer predict and uncouple pathological response and disease-free survival. Clin Cancer Res. 2019;25(5):1535–1545. doi: 10.1158/1078-0432.CCR-18-2365.
   PubMed Web of Science ®Google Scholar
• Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):1–26. doi: 10.1186/s12943-020-01238-x.
   PubMed Web of Science ®Google Scholar
• Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P, Rizzello V, Cipollone G, Navarra G, Mingari MC, Moretta L, et al. CD56 bright perforin low Noncytotoxic human NK cells are abundant in both healthy and Neoplastic solid Tissues and recirculate to secondary lymphoid organs via Afferent Lymph. J Immunol. 2014;192(8):3805–3815. doi: 10.4049/jimmunol.1301889.
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863–875. doi: 10.1002/cncr.23239.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011;71(21):6621–6632. doi: 10.1158/0008-5472.CAN-11-0792.
   PubMed Web of Science ®Google Scholar
• Ladoire S, Arnould L, Mignot G, Apetoh L, Rébé C, Martin F, Fumoleau P, Coudert B, Ghiringhelli F. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer. 2011;105(3):366–371. doi: 10.1038/bjc.2011.261.
   PubMed Web of Science ®Google Scholar
• Slattery K, Woods E, Zaiatz-Bittencourt V, Marks S, Chew S, Conroy M, Goggin C, Maceochagain C, Kennedy J, Lucas S, et al. TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer. J Immunother Cancer. 2021;9(2):e002044. doi: 10.1136/jitc-2020-002044.
   PubMed Web of Science ®Google Scholar
• Krneta T, Gillgrass A, Chew M, Ashkar AA. The breast tumor microenvironment alters the phenotype and function of natural killer cells. Cell Mol Immunol. 2016;13(5):628–639. doi: 10.1038/cmi.2015.42.
   PubMed Web of Science ®Google Scholar
• Morel E, Bellon T. HLA class I molecules regulate IFN-γ production induced in NK cells by Target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j. J Immunol. 2008;181(4):2368–2381. doi: 10.4049/jimmunol.181.4.2368.
   PubMed Web of Science ®Google Scholar
• Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, et al. 2015. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. Eur J Immunol. 45(5):1560–1569. doi: 10.1002/eji.201445353.
   PubMed Web of Science ®Google Scholar
• Favier B, LeMaoult J, Lesport E, Carosella ED. ILT2/HLA‐G interaction impairs NK‐cell functions through the inhibition of the late but not the early events of the NK‐cell activating synapse. FASEB J. 2010;24(3):689–699. doi: 10.1096/fj.09-135194.
   PubMed Web of Science ®Google Scholar
• Di Blasio S, van Wigcheren GF, Becker A, van Duffelen A, Gorris M, Verrijp K, Stefanini I, Bakker GJ, Bloemendal M, Halilovic A, et al. The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. Nat Commun. 2020;11(1):1–17. doi: 10.1038/s41467-020-16583-0.
   PubMed Web of Science ®Google Scholar
• Michea P, Noël F, Zakine E, Czerwinska U, Sirven P, Abouzid O, Goudot C, Scholer-Dahirel A, Vincent-Salomon A, Reyal F, et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat Immunol. 2018;19(8):885–897. doi: 10.1038/s41590-018-0145-8.
   PubMedGoogle Scholar
• Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, et al. 2023. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer. Breast Cancer Res. 25(1):1–19. doi: 10.1186/s13058-023-01717-1.
   PubMed Web of Science ®Google Scholar
• Wang XQ, Danenberg E, Huang CS, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Anton A, et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023;621(September):868–876. doi: 10.1038/s41586-023-06498-3.
   PubMedGoogle Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi: 10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 8(8):793–800. doi: 10.1038/nm730.
   PubMed Web of Science ®Google Scholar
• Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, Escors D. PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells. EMBO Mol Med. 2011;3(10):581–592. doi: 10.1002/emmm.201100165.
   PubMed Web of Science ®Google Scholar
• Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, Kuchroo VK, Freeman GJ, Sharpe AH. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci. 2004;101(29):10691–10696. doi: 10.1073/pnas.0307252101.
   PubMed Web of Science ®Google Scholar
• Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 2017;20(8):1818–1829. doi: 10.1016/j.celrep.2017.07.075.
   PubMed Web of Science ®Google Scholar
• Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, Thennavan A, Wang C, Torpy JR, Bartonicek N, et al. 2021. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 53(9):1334–1347. doi: 10.1038/s41588-021-00911-1.
   PubMed Web of Science ®Google Scholar
• Ren X, Wu H, Lu J, Zhang Y, Luo Y, Xu Q, Shen S, Liang Z. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. Cancer Biol Ther. 2018;19(5):373–380. doi: 10.1080/15384047.2018.1423919.
   PubMed Web of Science ®Google Scholar
• Yeong J, Lim JCT, Lee B, Li H, Ong CCH, Thike AA, Yeap WH, Yang Y, Lim AYH, Tay TKY, et al. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. J Immunother Cancer. 2019;7(1):1–13. doi: 10.1186/s40425-019-0499-y.
   PubMedGoogle Scholar
• Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, Varypataki EM, Richard M, Bommer E, Sam J, et al. 2022. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. 610(7930):161–172. doi: 10.1038/s41586-022-05192-0.
   PubMed Web of Science ®Google Scholar
• Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S, et al. Intratumoral Tcf1 + PD-1 + CD8 + T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50(1):195–211.e10. doi: 10.1016/j.immuni.2018.12.021.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. CD11c+CD8+ T cells: Two-faced adaptive immune regulators. Cell Immunol. 2010;264(1):18–22. doi: 10.1016/j.cellimm.2010.05.010.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kim CH, Choi BK, Kwon BS. Origins and functional basis of regulatory CD11c+CD8+ T cells. Eur J Immunol. 2009;39(6):1552–1563. doi: 10.1002/eji.200839057.
   PubMed Web of Science ®Google Scholar
• Beyer M, Wang H, Peters N, Doths S, Koerner-Rettberg C, Openshaw PJM, Schwarze J. The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respir Res. 2005;6(1):1–11. doi: 10.1186/1465-9921-6-70.
   PubMedGoogle Scholar
• Qualai J, Li LX, Cantero J, Tarrats A, Fernández MA, Sumoy L, Rodolosse A, McSorley SJ, Genescà M, Reeves RK. Expression of CD11c is associated with unconventional activated T cell subsets with high migratory potential. PLoS ONE. 2016;11(4):1–22. doi: 10.1371/journal.pone.0154253.
   Web of Science ®Google Scholar
• Takeda Y, Azuma M, Matsumoto M, Seya T. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8+ T cells during vaccine immunotherapy. J Exp Clin Cancer Res. 2016;35(1):1–16. doi: 10.1186/s13046-016-0416-x.
   PubMedGoogle Scholar